Cytotoxic T lymphocytes promote cytarabine-induced acute myeloid leukemia cell apoptosis via inhibiting Bcl-2 expression

Experimental and Therapeutic Medicine

Volumn 14, Issue 2, 2017, Pages 1081-1085

  Deng, Rui ^a   Fan, Fang Yi ^a   Yi, Hai ^a   Fu, Li ^a   Zeng, Yan ^a   Wang, Yi ^a   Miao, Xiao Juan ^a   Shuai, Yan Rong ^a   Su, Yi ^a  

^a CHENGDU MILITARY GENERAL HOSPITAL   (China)

Author keywords

Acute myeloid leukemia cells; B cell lymphoma 2; Cytarabine; Cytotoxic T lymphocytes; Immunotherapy

Indexed keywords

CYTARABINE; PROTEIN BCL 2;

ACUTE MYELOID LEUKEMIA; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; MTT ASSAY; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 85023750573     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2017.4620     Document Type: Article

References (30)

1. Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J, Pounds S, Razzouk BI, Lacayo NJ, Cao X, et al: Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: Results of the AML02 multicentre trial. Lancet Oncol 11: 543-552, 2010.
2. Niewerth D, Creutzig U, Bierings MB and Kaspers GJ: A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood 116: 2205-2214, 2010.
3. Couzin-Frankel J: Breakthrough of the year 2013. Cancer immunotherapy. Science 342: 1432-1433, 2013.
4. Greiner J, Schmitt M, Li L, Giannopoulos K, Bosch K, Schmitt A, Dohner K, Schlenk RF, Pollack JR, Dohner H and Bullinger L: Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. Blood 108: 4109-4117, 2006.
5. Castella B, Vitale C, Coscia M and Massaia M: Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: From bench to bedside. Cell Mol Life Sci 68: 2419-2432, 2011.
6. Van Driessche A, Berneman ZN and Van Tendeloo VF: Active specific immunotherapy targeting the wilms’ tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: Lessons from early clinical trials. Oncologist 17: 250-259, 2012.
7. Brossart P, Schneider A, Dill P, Schammann T, Grünebach F, Wirths S, Kanz L, Bühring HJ and Brugger W: The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res 61: 6846-6850, 2001.
8. Theobald M, Biggs J, Hernández J, Lustgarten J, Labadie C and Sherman LA: Tolerance to p53 by A2. 1-restricted cytotoxic T lymphocytes. J Exp Med 185: 833-841, 1997.
9. Burstein HJ and Schwartz RS: Molecular origins of cancer. N Engl J Med 358: 527, 2008.
10. Berger C, Turtle CJ, Jensen MC and Riddell SR: Adoptive transfer of virus-specific and tumor-specific T cell immunity. Curr Opin Immunol 21: 224-232, 2009.
11. Brimnes MK, Gang AO, Donia M, Thor Straten P, Svane IM and Hadrup SR: Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion. Cancer Immunol Immunother 61: 1221-1231, 2012.
12. Hirohashi Y, Torigoe T, Inoda S, Morita R, Kochin V and Sato N: Cytotoxic T lymphocytes: Sniping cancer stem cells. Oncoimmunology 1: 123-125, 2012.
13. Falkenburg JF, Wafelman AR, Joosten P, Smit WM, van Bergen CA, Bongaerts R, Lurvink E, van der Hoorn M, Kluck P, Landegent JE, et al: Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 94: 1201-1208, 1999.
14. Yee C, Thompson J, Byrd D, Riddell SR, Roche P, Celis E and Greenberg PD: Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 99: 16168-16173, 2002.
15. Bracci L, Schiavoni G, Sistigu A and Belardelli F: Immune-based mechanisms of cytotoxic chemotherapy: Implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ 21: 15-25, 2014.
16. Ramakrishnan R, Huang C, Cho HI, Lloyd M, Johnson J, Ren X, Altiok S, Sullivan D, Weber J, Celis E and Gabrilovich DI: Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy. Cancer Res 72: 5483-5493, 2012.
17. Ramakrishnan R, Assudani D, Nagaraj S, Hunter T, Cho HI, Antonia S, Altiok S, Celis E and Gabrilovich DI: Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 120: 1111-1124, 2010.
18. Shurin GV, Tourkova IL, Kaneno R and Shurin MR: Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol 183: 137-144, 2009.
19. English D and Andersen BR: Single-step separation of red blood cells. Granulocytes and mononuclear leukocytes on discontinuous density gradients of Ficoll-Hypaque. J Immunol Methods 5: 249-252, 1974.
20. Deng R, Wang SM, Yin T, Ye TH, Shen GB, Li L, Zhao JY, Sang YX, Duan XG and Wei YQ: Inhibition of tumor growth and alteration of associated macrophage cell type by an HO-1 inhibitor in breast carcinoma-bearing mice. Oncol Res 20: 473-482, 2013.
21. Kruger NJ: The Bradford Method for Protein Quantitation. Methods Mol Biol 32: 9-15, 1994.
22. Garnett CT, Schlom J and Hodge JW: Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: Effects of docetaxel on immune enhancement. Clin Cancer Res 14: 3536-3544, 2008.
23. Gelbard A, Garnett CT, Abrams SI, Patel V, Gutkind JS, Palena C, Tsang KY, Schlom J and Hodge JW: Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clin Cancer Res 12: 1897-1905, 2006.
24. Gameiro SR, Caballero JA, Higgins JP, Apelian D and Hodge JW: Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses. Cancer Immunol Immunother 60: 1227-1242, 2011.
25. Nowak AK, Robinson BW and Lake RA: Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 63: 4490-4496, 2003.
26. Hill SC, Youde SJ, Man S, Teale GR, Baxendale AJ, Hislop A, Davies CC, Luesley DM, Blom AM, Rickinson AB, et al: Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. J Immunol 174: 41-50, 2005.
27. Vanneman M and Dranoff G: Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 12: 237-251, 2012.
28. Zhang T and Herlyn D: Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer. Cancer Immunol Immunother 58: 475-492, 2009.
29. Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, Hoffman L, Aguilar B, Chang WC, Bretzlaff W, et al: T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood 122: 3138-3148, 2013.
30. Wang QS, Wang Y, Lv HY, Han QW, Fan H, Guo B, Wang LL and Han WD: Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther 23: 184-191, 2015.